Xinyi Zhang, Miner Shao, Jie Yao, Lufeng Zhao, Lili Li, Mengyao Chen, Yixin Zhang, Huiying Liu, Zexin Chen, Baizhou Li, Zuqun Wu, Junqiang Fan, Fuming Qiu
Immune checkpoint inhibitors (ICIs) plus chemotherapy has demonstrated efficacy in resectable non-small-cell lung cancer (NSCLC), yet the optimal period of neoadjuvant immunochemotherapy is undetermined. In a phase II study (neoSCORE, NCT04459611), more neoadjuvant therapy cycles appeared to provide greater pathological remission, and patients with squamous NSCLC had a better major pathological response rate than those with nonsquamous NSCLC. Sintilimab, a monoclonal anti-PD-1 antibody, has shown encouraging antitumor activity and safety in multiple cancers, including NSCLC...
February 14, 2024: Future Oncology